Cipla

CIPLA · NSE · India

Public Market Listing

CIPLANSE

NSE primary exchange listing

Live quotes, historical charts, and market capitalization for Cipla are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
1Approved
1Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
InsulinPeptide
Type 2 DiabetesType 1 Diabetes
Vildagliptin(Galvus)
Phase 3
DPP-4Small molecule
Type 2 Diabetes
Phase 2
fungal CYP51 (lanosterol 14α-demethylase)Small molecule
Allergic Bronchopulmonary Aspergillosis

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
March 2027 (1)
AfrezzaPhase 2Type 1 Diabetes Mellitus
Est. primary completion 2027-03 · NCT07224321 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 August 2026Topline resultItraconazole (PUR1900)Cipla completed its Phase 2 of inhaled itraconazole (PUR1900) in India with positive results; India's CDSCO approved a Phase 3
Cipla · Source ↗
29 May 2026ApprovalAfrezzaFDA approves Afrezza for pediatric use (ages 6+)
US, FDA · Source ↗

Financial reports

No financial reports recorded.